Abstract
MicroRNAs (miRNAs) have been implicated in the regulation of gene expression across various biological processes, including host responses to viral infections. The 2009 pandemic H1N1 influenza virus is an emerging reassortant strain that can cause severe illness. To understand its molecular pathogenesis, we profiled cellular miRNAs in the lungs of BALB/c mice infected with the wild-type 2009 pandemic strain A/Beijing/501/2009 (BJ501) and the mouse-adapted A/Puerto Rico/8/1934 (PR8) strain. Microarray analysis revealed strain- and temporal-specific miRNA expression patterns. Notably, more differentially expressed (DE) miRNAs were observed on day 5 post-infection than on day 2, with a general trend toward up-regulation. We identified 47 unique DE miRNAs, including 32 with known roles in immunity and antiviral activity, such as miR-155 and miR-223. Pathway enrichment analysis identified the transforming growth factor-β (TGF-β) signaling pathway as a key cellular target. These findings provide the first miRNA expression profiles for the 2009 pandemic H1N1 virus in a mouse model, offering potential novel therapeutic targets.
Introduction
While the clinical impact of the 2009 H1N1 pandemic is well-documented, the underlying molecular "tug-of-war" between the virus and the host remains partially obscured. Specifically, the role of microRNAs—small, non-coding RNA molecules that act as post-transcriptional "dimmer switches" for gene expression—was a major knowledge gap for this specific pandemic strain. Understanding which miRNAs are activated or suppressed during infection is crucial because these molecules regulate the host's immune response, inflammation, and viral replication. By mapping these profiles, researchers can identify potential biomarkers for disease severity or novel therapeutic targets that could "re-tune" the host response to improve survival.
Materials and Methods
This study utilized a comparative approach in a BALB/c mouse model. Mice were infected with either the wild-type 2009 pandemic strain (BJ501) or a mouse-adapted laboratory strain (PR8). Lung tissues were harvested at 2 and 5 days post-infection (dpi). The research team employed Agilent Mouse miRNA microarrays to profile 938 different miRNAs. To ensure technical reliability, nine key miRNAs were validated using Real-time RT-PCR. Bioinformatics tools, including TargetScan 6.2 and DAVID 6.7, were used to predict messenger RNA (mRNA) targets and identify affected biological pathways. The resulting expression matrix has been deposited in the Gene Expression Omnibus (GEO) database under accession number GSE46087.
Results
Temporal Escalation and Up-regulation Bias
The host regulatory response showed significant temporal progression. Microarray data revealed a marked increase in the number of differentially expressed miRNAs as the infection progressed from 2 dpi to 5 dpi. Furthermore, for both viral strains, the majority of affected miRNAs were up-regulated rather than suppressed. This suggests that the host actively deploys these regulatory molecules, likely in an attempt to modulate the escalating inflammatory response as the infection moves toward full-blown pulmonary inflammation.
Strain-Specific and Common miRNA Signatures
The study identified a total of 47 unique miRNAs significantly altered (at least a 2-fold change) during infection. While BJ501 and PR8 shared many regulatory features, they also exhibited strain-specific signatures. PR8 provoked a broader miRNA response (43 DE miRNAs) compared to BJ501 (29 DE miRNAs), which may correlate with differences in virulence and adaptation. Of these 47 miRNAs, 32 have known roles in cancer, immunity, or antiviral activity (such as miR-155 and miR-223), while 15 have no previously reported function.
Pathway Enrichment: The TGF-β Hub
Pathway enrichment analysis of predicted targets pointed directly to the Transforming Growth Factor-beta (TGF-β) signaling pathway as the primary target for both strains. As a master regulator of cell cycle control, inflammation, and tissue repair, the modulation of TGF-β by miRNAs likely contributes to the severe lung pathology, such as pneumonia and edema, characteristic of H1N1 infection. Other top enriched pathways included adherens junction and axon guidance, suggesting a conserved viral strategy for disrupting lung tissue integrity.
Discussion
This study provides a foundational "parts list" for the regulatory response to 2009 H1N1. However, some limitations remain. First, the lack of parallel mRNA profiling means the actual silencing effect of these miRNAs on their predicted targets remains hypothetical until confirmed by transcriptomic or proteomic data. Second, the study is primarily descriptive; future functional validation involving "knockdown" or "overexpression" experiments for candidates like miR-155 or miR-223 is necessary to determine if manipulating these molecules can reduce viral titers or lung damage in vivo. Despite these limitations, the identification of these 47 miRNAs moves the field closer to developing precision therapies for severe influenza.
Summary updated